Latest Industry Insights

Technology Networks spoke with Dr. Jenny Bailey Cooper, co-founder and CEO of Ferryx, to learn the science behind its lead product, Ferrocalm^TM, and how its innovative strategy could reshape the future of gut health.

Portal Bio’s microfluidic technology enhances drug discovery and cell engineering by enabling efficient, scalable molecular delivery for sensitive cell types.

At the BioTrinity 2025 conference, Technology Networks spoke with Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe, who are utilizing synthetic biology to engineer bacteria capable of breaking down the barriers within tumors.

In this article, Technology Networks spoke with Dr. Jack Hoppin and Dr. John Babich from Ratio Therapeutics to learn more about the recent radiopharmaceutical revolution.

To explore how PROTACs are transforming drug discovery, we spoke with Robyn Stoller, business development manager at Cytiva.

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ADCs.

Technology Networks spoke to Jason Barker, ND, clinical lab educator at Vibrant Wellness, to explore why co-infections from tick bites are frequently underdiagnosed and to examine current and future testing protocols of tick-borne diseases.

In this interview, Technology Networks spoke with Dr. Francesco Dell’Accio and Dr. Suzanne Eldridge to explore the impact of osteoarthritis on patients, the goals of ReFleks and a novel approach to repairing osteochondral defects.

In this interview, Sebastiaan J. Trietsch, Chief Technology Officer at MIMETAS, discusses how microphysiological systems are advancing drug discovery through scalable human-relevant models and AI integration.

A new pan-European network will integrate long-read sequencing into clinical practice, improving diagnosis of rare diseases and cancers.